An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Cancer Clinical Trials

Therapeutic Strategies to Target Activating Estrogen Receptor α

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative

More than Toxins—Current Prospects in Designing the Next

Therapeutic resistance to anti-oestrogen therapy in breast cancer

Tamoxifen off-target effects in macrophages. Tamoxifen regulates

ZB716, a steroidal selective estrogen receptor degrader (SERD), is

CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1

Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer - ScienceDirect

Novel endocrine therapies: What is next in estrogen receptor

An Expert's Guide to SABCS 2023: A Preview of the Top Abstracts

Diagnostic Utility of Next-Generation Sequencing in Circulating

Randomized Phase II Trial of Fulvestrant Plus Everolimus or